Colchicine: A State‐of‐the‐Art Review

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Volumn 11, Issue 3, 1991, Pages 196-211

  Spino, Michael ^b   Read, Stanley E ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; TUBULIN;

AMYLOIDOSIS; BONE MARROW DEPRESSION; DRUG RESISTANCE; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MICROTUBULE; MITOSIS; MYOPATHY; NEUROPATHY; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PREGNANCY; PRIORITY JOURNAL; REVIEW;

AMYLOIDOSIS; ANIMAL; ARTHRITIS, GOUTY; CLINICAL TRIALS; COLCHICINE; DRUG RESISTANCE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMAN; MICROTUBULES; PREGNANCY;

EID: 0026040213     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/j.1875-9114.1991.tb02629.x     Document Type: Review

References (168)

1. History of use of Colchicum and related medicaments in gout with suggestions for further research
2. Colchicum, the panacea
3. Examen clinique de plusieurs vegetaux de la famille des colchicées et du principe actif quils renferment
4. Structure of colchicine
5. Structure of the mitotic spindle inhibitor colcemid, N‐desacetyl‐N‐methylcolchicine
6. An x‐ray diffraction determination of the chemical structure of colchicine
7. The biochemical events of mitosis. I. Synthesis and properties of colchicine labeled with tritium in its acetyl moiety
8. Underwandlung des colchizins durch sonnenlicht
9. The biochemical events of mitosis. II. The in vivo and in vitro binding of colchicine in grasshopper embryo and its possible relation to the inhibition of mitosis
10. Photoisomerization of colchicine. Loss of significant antimitotic activity in human lymphocytes
11. Uber die trennung und mitosewirkung der lumicolchicine
12. Colchicine‐sensitive microtubules
13. Interaction of tubulin with single ring analogues of colchicine
14. Podophyllotoxin as a probe for the colchicine binding site of tubulin
15. Role of B‐ring of colchicine in its binding to tubulin
16. Colchicine analogs in the treatment of acute gout
17. Colchicine. Clinical pharmacology in acute gouty arthritis
18. Polymorphonuclear leukocyte mobility in vitro. III. Possible release of chemotactic substance after phagocytosis of urate crystals by polymorphonuclear leukocytes
19. Studies on crystal‐induced chemotactic factor. I. Requirement for protein synthesis and neutral protease activity
20. Polymorphonuclear leukocyte motility in vitro. IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals
21. Mechanism of action of colchicine in acute urate crystal‐induced arthritis
22. The action of colchicine in acute gout
23. The action of colchicine in acute gouty arthritis
24. Colchicine and new antiinflammatory drugs for the treatment of acute gout
25. Mechanism of action of colchicine. V. Neutrophil adherence and phagocytosis in patients with acute gout treated with colchicine
26. Changes in membrane microviscosity associated with phagocytosis: effects of colchicine
27. Polarization of endocytosis and receptor topography on cultured macrophages
28. Control of cell surface topography
29. Inhibition and reversal of capping by cytochalasin B, vinblastine and colchicine
30. Direct evidence for a colchicine‐induced impairment in the mobility of membrane components
31. Effects of colchicine and colchemid on synthesis of deoxyribonucleic acid in the skin of the guinea pig's ear in vitro
32. Depression of DNA synthesis and mitotic index by colchicine in cultured human lymphocytes
33. Autoradiographic study of colchicine inhibition of DNA synthesis and cell migration in hairless mouse epidermis in vivo
34. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever
35. In vitro production of SAA by mouse hepatocytes
36. Mouse amyloid protein AA: homology with nonimmunoglobulin protein of human and monkey amyloid substance
37. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils
38. Effect of colchicine on cyclic AMP levels in human leukocytes
39. Colchicine
40. Plasma levels of colchicine after oral administration of a single dose
41. Purification of colchicine, its photoisomer(s), and some congeners by paper and thin‐layer chromatography
42. Colchicine plasma levels: implication as to pharmacology and mechanisms of action
43. A sensitive radioimmunoassay for colchicine
44. Colchicine kinetics in patients with familial Mediterranean fever
45. Bindings of drugs by albumin and plasma protein
46. Distribution of radioactive colchicine in some organs of normal and tumor‐bearing mice
47. Studies with radioactive colchicine; influence of tumors on tissue distribution of radioactive colchicine in mice
48. Measurement of colchicine in urine and peripheral leukocytes
49. Bioavailability and pharmacokinetics of two colchicine formulations in 12 volunteers
50. Biliary excretion of colchicine
51. Gout
52. Bone marrow depression associated with acute colchicine toxicity in the presence of hepatic dysfunction
53. Colchicine toxicity
54. Diagnostic value of the colchicine therapeutic trial
55. Therapeutic test with colchicine in diagnosis of gout
56. Colchicine for familial Mediterranean fever [letter]
57. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever
58. Colchicine therapy for familial Mediterranean fever. A double‐blind trial
59. Colchicine in familial Mediterranean fever
60. Daily prophylactic colchicine in familial Mediterranean fever
61. Allergic reaction and desensitisation of colchicine in familial Mediterranean fever
62. Prolonged colchicine treatment in four patients with amyloidosis
63. Colchicine therapy in amyloidosis. A preliminary report
64. Colchicine in the treatment of cirrhosis of the liver
65. Effects of colchicine on collagenase in cultures of rheumatoid synovium
66. Effect of colchicine on collagen, albumin and transferrin synthesis by cirrhotic rat liver slices
67. A prospective trial of colchicine for primary biliary cirrhosis
68. Topical colchicine therapy for recalcitrant psoriasis
69. Colchicine in dermatologic therapy
70. Leucocyte movement of colchicine treatment in Behçet's disease
71. Colchicine in Behçet's disease
72. Treatment of dermatitis herpetiformis with colchicine
73. Long‐term evaluation of colchicine in the treatment of scleroderma
74. Mitosagifte und coniserende strahlung
75. Topical treatment of penile condylomata acuminata with colchicine at 48–72 hour intervals
76. Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis
77. Colchicine in the treatment of Paget disease of bone: a new therapeutic approach
78. Intravenous colchicine in treatment of acute pseudogout
79. Colchicine and pseudogout
80. Colchicine‐quinine therapy for acute Falciparum malaria acquired in Vietnam
81. Colchicine therapy for refractory idiopathic thrombocytopenic purpura
82. Oral colchicine for the treatment of experimental traction retinal detachment
83. Proceedings: effects on prostaglandin biosynthesis of drugs affecting gastrointestinal function
84. Accidents thérapeutiques mortels après colchicine intraveineuse
85. Intoxication aigue par la colchicine
86. Drug‐induced malabsorption
87. 12 malabsorption in patients receiving colchicine
88. Steatorrhoea and jejunal reticulum cell sarcoma occurring in a patient on long‐term colchicine therapy for gout
89. Colchicine use for familial Mediterranean fever
90. Colchicine myopathy and neuropathy
91. Acute toxicity after excessive ingestion of colchicine
92. Colchicine toxicity. A multisystem disease
93. Effects of colchicine on myofilament arrangement and the lysosomal system in skeletal muscle
94. Nerve destruction by colchicine in mice and golden hamsters
95. Influence of colchicine on the form of skeletal muscle in tissue culture
96. Colchicine. I. General pharmacology
97. Chronic human colchicine neuropathy and myopathy
98. Inhibition of axoplasmic transport by colchicine, podophyllotoxin, and vinblastine: an effect on microtubule
99. Lysosomes are associated with microtubules and not with intermediated filaments in cultured fibroblasts
100. Effect of colchicine on human tissues
101. Marrow aplasia induced by colchicine: a case report
102. Etude d'hemostase au cours des intoxications aigues par la colchicine
103. Donnees actuelles sur I'intoxication aigue par la colchicine
104. Colchicine overdose
105. Colchicine intoxication. A reappraisal of its pathology based on a study of three fatal cases
106. Effect of colchicine on human carcinoma
107. Colchicine with special reference to its mode of action and effects on bone marrow
108. Effect of colchicine on T cell subsets of healthy volunteers
109. Intoxication volontaire par 30 mg de colchicine chez une jeune fille de 18 ans. Evolution bénigne
110. Discussion
111. A review of toxic epidermal necrolysis in Britain
112. Haarausfal und haarveränderungen nach kolchizintherapie
113. Colchicine alopecia
114. Hypersensitivity to colchicine
115. Colchicine overdose: report of two cases and review of the literature
116. Acute ascending polyneuropathy and dermatitis following poisoning by tubers of Gloriosa superba
117. Massive colchicine overdose: a report on the toxicity
118. Haemodynamic studies in eight cases of acute colchicine poisoning
119. Colchicine poisoning as a mode of suicide
120. Aplasie médullaire après intoxication aiguëà la colchicine
121. Fatal colchicine poisoning in a boy with familial Mediterranean fever
122. Colchicine
123. Drug administration in renal failure
124. Drug therapy in renal failure: dosing guidelines for adults
125. Avoiding complications with IV colchicine
126. Colchicine teratogenesis in hamster embryos
127. Teratogenic and cytogenic effects of some plant‐derived antitumour agents (vincristine, colchicine, maytansine, VP‐16–213 and VM‐26) in mice
128. Effect of N‐desacetylthiocolchicine (TC) and N‐desacetylmethyl‐colchicine (MC) on rat fetus and litter in utero
129. The action of various agents on the rabbit embryo
130. Compound interferring with ovum implantation and development. I. Alkaloids and antimetabolites
131. Artificial production of monstrosities in rabbit
132. The action of some nucleotoxic substances on pregnancy
133. Sur Taction tératogène de quelques substances antimitotiques chez le rat. [The teratogenic action of some antimitotic substances in rats.]
134. Preliminary notes on the teratogenic and embryocidal effects of colchicine on mouse embryos
135. Comparative teratogenic studies with various therapeutic agents in mice and rabbits
136. Colchicine in the preventive treatment of the rubella embryopathy
137. The effect of colchicine on the rat embryo
138. Trisomy after colchicine therapy
139. Trisomy after colchicine therapy
140. Trisomy after colchicine therapy [letter]
141. Cystinuria associated with mongolism and identification of an abnormal pyrrolidine compound in urine
142. The use of nitrogen mustard in the management of two pregnant lymphoma patients
143. Colchicine. Infertility incidence study
144. Azoospermia caused by colchicine—a case report
145. Colchicine for familial Mediterranean fever: possible adverse effects
146. Colchicine and testicular function in man
147. A case of human reproductive abnormalities possibly induced by colchicine treatment
148. A cytogenetic evaluation of long‐term colchicine therapy in the treatment of familial Mediterranean fever (FMF)
149. Drug‐resistant mutant of Chinese hamster ovary cells possess an altered cell surface carbohydrate component
150. Resistance to multiple chemotherapeutic agents in human cancer cells
151. Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis‐diamminedichloroplatinum (II)
152. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF‐CEM cells after short‐term, high‐dose treatment with this drug
153. A structural gene mutation affecting the regulatory subunit cAMP‐dependent protein kinase in mouse lymphoma cells
154. Isolation of multiple classes of mutant CHO cells resistant to cAMP
155. High frequency of mutation to tubericidine resistance in CHO cells
156. Glutathione metabolism as a determinant of therapeutic efficacy: a review
157. Multidrug resistance
158. Reduction in glutathione content of l‐PAM‐resistant L 1210 cells confers drug sensitivity
159. The mechanism of action of colchicine. Colchicine binding properties of sea urchin sperm tail outer doublet tubulin
160. Addition of colchicine‐tubulin complex to microtubule ends: the mechanism of substoichiometric colchicine poisoning
161. Taxol binds to cellular microtubules
162. Reduced permeability of CHO cells as a mechanism of resistance to colchicine
163. CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered b‐tubulin
164. Mutants of Chinese hamster ovary (CHO) cells with altered colcemid‐binding affinity
165. Complete sequence of three alpha‐tubulin cDNAs in Chinese hamster ovary cells: each encodes a distinct alpha‐tubulin isoprotein
166. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly